PLC () has filed a new patent application for its CDX antibody.
It covers its use in conditioning patients for bone marrow transplant and its deployment in a number of hard-to-treat blood borne diseases, including acute myeloid leukaemia (AML).
On the latter, the application covers the composition sequences of newly-discovered monoclonal antibodies against a target protein expressed on the surface of hematopoietic stem cells of certain types of leukaemia.
“Filing this patent is an important development and further solidifies Hemogenyx’s leadership position in the development of new methods of bone marrow transplantation and treatments for blood cancers such as AML, acute lymphoblastic leukemia and possibly others,” said Hemogenyx chief executive, Dr Vladislav Sandler.
“The antibody we are developing, CDX, should, if successful, provide a new, effective and safe method of conditioning patients for bone marrow transplants, and has the potential to be a superior pharmaceutical for the treatment of blood cancers, for which survival rates are currently very poor.”
- Facebook, Twitter, Google pause review of Hong Kong requests for user data
- Need a pulse oximeter? These models are still in stock, starting at $24
- The best video doorbell camera for 2020
- MCU Black Widow movie to pass the torch to Florence Pugh, report says
- The best wired streaming device to save your home Wi-Fi bandwidth
- 2021 Kia K5 priced from $24,455, just $100 more than current Optima
- Bird denies getting $10 million COVID-19 loan
- The best-sounding wireless earbuds: Sony, Sennheiser and more
- Hamilton on Disney Plus: First-timers debate whether it meets the hype